When Mylan filed its first abbreviated new drug application (ANDA) for a controlled-release oxycodone formulation, AstraZeneca’s legal team didn’t panic […]
Formulation Forensics: How to Read Excipient and Process Clues in Drug Patent Claims Read Post »
Biologic drugs represent 2% of all U.S. prescriptions but consume 37% of net drug spending. [1] That arithmetic explains everything
Every year, hundreds of millions of dollars shift hands based on a single question: who filed first? The Paragraph IV
The $236 Billion Blind Spot Every supply chain director in pharmaceuticals knows the standard risks: a manufacturer fails a GMP
Drug Patent Data: The Supply Chain Forecasting Edge Big Pharma Isn’t Talking About Read Post »
Generic drugs fill more than 90% of U.S. prescriptions yet capture only around 18% of total drug spending. That gap
8 Problems Killing Generic Pharma’s Margins (And How the Industry Is Fighting Back) Read Post »
The $300 Billion Window Procurement Teams Are Missing Between now and 2030, an estimated $300 billion in branded drug revenue
The pharmaceutical industry generates roughly $1.5 trillion in global revenues each year. It has survived opioid litigation, the Vioxx recall,
8 Brutal Problems Killing Branded Pharma’s Revenue Model Read Post »
Every branded drug with a patent is also a clock. Somewhere in the FDA’s Orange Book, a set of expiration
The FDA Orange Book Decoded: How Generic Drug Makers Find, Time, and Win Market Entry Read Post »
Every biopharma patent filing is a confession. It tells you what a company believes is worth protecting, who did the
Sign in or create a free account to read this DrugPatentWatch article
